Sign In
Buy IPSEY
$46.50
+1.11 (+2.45%)
At Close: Jun 23, 2026
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
04:10pm, Tuesday, 20'th May 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of p
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
12:00pm, Wednesday, 30'th Apr 2025
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANC
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
11:33am, Wednesday, 16'th Apr 2025
Ipsen S.A. (OTCPK:IPSEY) Q1 2025 Results Conference Call April 16, 2025 8:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Conference C
Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript
11:24am, Thursday, 13'th Feb 2025
Ipsen S.A. (OTCPK:IPSEY) Q4 2024 Earnings Call February 13, 2025 7:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Christelle Huguet -
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
06:30am, Thursday, 03'rd Oct 2024
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving t
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
02:14pm, Thursday, 29'th Aug 2024
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Prior to the approvals and launches of Iqirvo
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
07:45am, Friday, 26'th Jul 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the li
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
08:18am, Thursday, 25'th Jul 2024
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
05:22pm, Monday, 10'th Jun 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the li
Annual General Meeting of Ipsen S.A. held on 28 May 2024
12:00pm, Tuesday, 28'th May 2024
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (Fra
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
08:55am, Tuesday, 07'th May 2024
Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BIL
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
06:31pm, Friday, 05'th Apr 2024
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
